HCT-CI v.1
Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment.
To calculate HCT-CI score and predict survival after HCT in patients with hematologic malignancies.
HCT-CI Score is calculated from the following parameters: History of arrhythmia, Cardiac disease, Inflammatory bowel disease, Diabetes, Cerebrovascular disease, Psychiatric disturbance, Hepatic dysfunction, Obesity (BMI ≥35 kg/m²), Infection, Rheumatologic disease, Peptic ulcer, Renal dysfunction, Pulmonary dysfunction, Prior solid tumor, Type of transplant, Age and Intensity. Interpretation: Allo-HCT (All types of patients and transplants: nonmyeloablative, reduced-intensity conditioning, myeloablative conditioning): HCT-CI Score: 1-year: 0: 1-2: ≥ 3: NRM: 17% 21% 26% OS: 69% 62% 56% 3-year: NRM 24% 28% 35% OS 54% 47% 38% ASCT (autologous stem cell transplant): HCT-CI Score: 1-year: 0: 1-2: ≥ 3: NRM: 3% 3% 5% OS: 91% 88% 86% 3-year: NRM 5% 6% 9% OS 79% 73% 70% Age-adjusted HCT-CI 2-year 0 1–2 3–4 ≥5 NRM NMA: 5% NMA: 9% NMA: 17% NMA: 35% RIC: 12% RIC: 18% RIC: 36% RIC: 41% MAC: 10% MAC: 20% MAC: 37% MAC: 49% OS NMA: 81% NMA: 74% NMA: 59% NMA: 37% RIC: 87% RIC: 70% RIC: 50% RIC: 35% MAC: 79% MAC: 66% MAC: 45% MAC: 29% NRM, non-relapse mortality. OS, overall survival. NMA, nonmyeloablative. RIC, reduced-intensity conditioning. MAC, myeloablative conditioning
1. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
EVALUATION.hct_ci.v0, OBSERVATION.basic_demographic.v1, OBSERVATION.body_mass_index.v2
